Amy Hallman Rice

Cooley advised Valneva, a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs, on a debt facility for up to $500 million in nondilutive financing with funds managed by Pharmakon Advisors.

Cooley advised AttackIQ, a leading vendor of adversarial exposure validation solutions, on its acquisition of assets from DeepSurface Security, a security posture management and vulnerability prioritization company. Partner Matt Browne led the Cooley team advising AttackIQ.

Cooley advised Cortica, a leading provider of advanced neurological therapies for children with autism and other developmental differences, on its $80 million financing round, co-led by Morgan Health and Nexus NeuroTech Ventures.

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised MannKind, a company focusing on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases, on the sale of a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare for up to $200 million.